Recordati (REC) Q2 2024 earnings summary

Executive summary

• Net revenue for H1 2024 reached €1,185.7 million, up 13.5% year-over-year, driven by strong growth in both Specialty & Primary Care and Rare Diseases segments, with robust momentum across all geographies.

• EBITDA rose 11.5% to €452.9 million, with a margin of 38.2%, reflecting operating leverage despite a diluted gross margin from product mix.

• Adjusted net income increased 4.7% to €301.0 million, while reported net income declined 1.0% to €225.4 million due to higher tax rates and financial expenses.

• Free cash flow was €256.6 million, slightly down year-over-year due to higher interest and tax payments; net debt improved to €1,469.4 million, just below 1.8x EBITDA pro-forma.

• 2024 financial targets were revised upward, reflecting continued business strength and positive outlook.

Financial highlights

• Net revenue grew 13.5% year-over-year to €1,185.7 million; like-for-like growth at constant exchange rates was 10.2%.

• EBITDA margin was 38.2%; gross profit margin declined to 67.6% due to product/country mix and new product consolidation.

• Adjusted operating income was €370.4 million (+9.5%), representing 31.2% of net revenue.

• SG&A expenses were 27.1% of revenue; R&D expenses at 11.7% of revenue.

• EPS (basic) was €1.092 for H1 2024.

Outlook and guidance

• FY 2024 guidance raised: net revenue €2,300–2,340 million, EBITDA €845–865 million, adjusted net income €560–580 million, margin ~24.5%.

• EBITDA margin confirmed at approximately 37%.

• 2025 targets reaffirmed: revenue over €2.4 billion and EBITDA margin of ~37%.

• SPC expected to deliver mid-single digit organic growth at CER; RRD to maintain strong double-digit growth.

• FX headwind for FY 2024 estimated at around -2%.